|
Orthologous residues
|
|
Bim (human): S69‑p, Bim iso2 (human): ‑, Bim iso3 (human): ‑, Bim (mouse): S65‑p, Bim (rat): S65‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling, electrophoretic mobility shift, mutation of modification site
|
|
Disease tissue studied:
leukemia, chronic myelogenous leukemia, lymphoma, Burkitt's lymphoma
|
|
Relevant cell lines - cell types - tissues:
293 (epithelial), K562 (erythroid), RAMOS (B lymphocyte)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
ERK1 (human)
|
phospho-antibody, pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
phorbol ester
|
|
|
|
increase
|
|
|
U0126
|
phorbol ester
|
|
|
inhibit treatment-induced increase
|
|
|
GF109203X
|
phorbol ester
|
|
|
inhibit treatment-induced increase
|
|
|
SB203580
|
phorbol ester
|
|
|
no effect upon treatment-induced increase
|
|
|
LY294002
|
phorbol ester
|
|
|
no effect upon treatment-induced increase
|
|
|
tamoxifen
|
|
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
protein degradation
|
|
Effect of modification (process):
apoptosis, inhibited
|
